Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2024

Genmab — November 2024

Planlagt Fastgjort Låst Flyttet Genmab
724 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • A Offline
    A Offline
    Aaanditsgone
    wrote on sidst redigeret af
    #628

    Var det en gammel nyhed, at epco har hurtigere markedspenetration i Japan end dara havde? Ingen har nævnt det.

    1 Reply Last reply
    0
    • A Offline
      A Offline
      Aaanditsgone
      wrote on sidst redigeret af
      #629

      Glæder mig til marts, når erzo forhåbentlig ikke stjæler al opmærksomheden fra epco længere

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #630

        Du har lidt ret i at epco er en succeshistorie, som vi let tager for givet. Epco ta’r kegler på kommende ASH. Og fremtiden tegner lys for epco i alskens indikationer. Problemet er bare at der får flere år før den når frem i 1. linje.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #631

          No, it was new news 😉 and he said epco was the fastes oncology drug launch in Japan. head start to competition about a year if i remember well what he said.

          1 Reply Last reply
          0
          • royalR Offline
            royalR Offline
            royal
            wrote on sidst redigeret af
            #632

            Nu skal vi max. sove 100 gange mere inden JnJ melder ud. 🙂

            1 Reply Last reply
            0
            • N Offline
              N Offline
              NiklasZ
              wrote on sidst redigeret af
              #633

              Måske Plan B aldrig bliver relevant...

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Stroka
                wrote on sidst redigeret af
                #634

                Genmab-partneren Novartis hæver de mellemlange prognoser https://proinvestor.com/investornyt/1245446/genmab-partneren-novartis-haever-de-mellemlange-prognoser

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #635

                  Nej, men det havde været passende, hvis Winkel kunne forklare markedet, at de klarer sig fint i tilfælde af opt out.

                  1 Reply Last reply
                  0
                  • D Offline
                    D Offline
                    deleted-user
                    wrote on sidst redigeret af
                    #636

                    Syns generelt Winkel har været alt for lukket omkring investeringer og ROI forventninger og har været alt for luftig med sin overfladiske omtale af, "at maksimere potentialet". Nu lyder det til, at man vil åbne op for noget der ligner langsigtet mål og forventninger (læs: målbare) i starten af 2025 og omtale markeder og størrelser. Det tror jeg nogle prof analytikere vil hilse velkommen inkl. mig selv, selvom jeg ikke er prof.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #637

                      tepezza being rolled out in Japan https://www.tepezza-pts.jp/

                      1 Reply Last reply
                      0
                      • D Offline
                        D Offline
                        deleted-user
                        wrote on sidst redigeret af
                        #638

                        Nu siger

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #639

                          I am fascinated how fast Amivantamab competitor
                          GEN1286
                          is being brought into the clinic, and I wonder if it will play a roll in the Hexabody-CD38 negotiations with JNJ (pure speculation)

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            Plimsoller
                            wrote on sidst redigeret af
                            #640

                            I thought exactly the same E L. Concerning your comments regarding the communication, I heard the Jefferies talk, and that was good. My concern when it comes to communication is more the ongoing part outside these events, and the explanatory part when they actually do present e.g. topline data. Even the experts in here are struggling to understand what is up and down when it comes to these results. It must be possible to do that better to keep interpretations and confusion to a minimum.

                            1 Reply Last reply
                            0
                            • J Offline
                              J Offline
                              JKY_VH
                              wrote on sidst redigeret af
                              #641

                              Enig Bulder 09.54. Gad vide om JW er så sikker i sin sag, at han ganske enkelt ikke kan forestille sig den situation?

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #642

                                Genmab-partner opjusterer https://borsen.dk/nyheder/virksomheder/genmab-partner-opjusterer / Novartis upgrades sales forecast https://www.investing.com/news/stock-market-news/novartis-upgrades-sales-forecast-3734168

                                1 Reply Last reply
                                0
                                • A Offline
                                  A Offline
                                  Aaanditsgone
                                  wrote on sidst redigeret af
                                  #643

                                  Når Pagano gentagne gange har sagt, at konsensus for OPEX ligger et passende sted, så tyder det i hvert fald ikke på, at de regner med selv at skulle financiere en masse erzo studier er 2025

                                  1 Reply Last reply
                                  0
                                  • A Offline
                                    A Offline
                                    Aaanditsgone
                                    wrote on sidst redigeret af
                                    #644

                                    i 2025*

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Raun
                                      wrote on sidst redigeret af
                                      #645

                                      @Bulder kl. 9.54 - Vend den om. - Det er kun nødvendigt med en plan B, hvis man er usikker på plan A

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #646

                                        https://www.novartis.com/sites/novartis_com/files/meet-novartis-management-2024-ceo-presentation.pdf novartis-2024-presentation

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #647

                                          in Jan24 Novartis had Kesimpta peak sales estimate $4bn, so to $6bn is a big step in a short period

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper